Portal de Periódicos da CAPES

Mildly Oxidized Low Density Lipoprotein Induces Contraction of Human Endothelial Cells through Activation of Rho/Rho Kinase and Inhibition of Myosin Light Chain Phosphatase

1999; Elsevier BV; Volume: 274; Issue: 43 Linguagem: Inglês

10.1074/jbc.274.43.30361

1083-351X

Markus Essler, Michaela Retzer, Markus Bauer, Johan W. M. Heemskerk, Martin Aepfelbacher, Wolfgang Siess,

Protein Tyrosine Phosphatases

Mildly oxidized low density lipoprotein (mox-LDL) is critically involved in the early atherogenic responses of the endothelium and increases endothelial permeability through an unknown signal pathway. Here we show that (i) exposure of confluent human endothelial cells (HUVEC) to mox-LDL but not to native LDL induces the formation of actin stress fibers and intercellular gaps within minutes, leading to an increase in endothelial permeability; (ii) mox-LDL induces a transient decrease in myosin light chain (MLC) phosphatase that is paralleled by an increase in MLC phosphorylation; (iii) phosphorylated MLC stimulated by mox-LDL is incorporated into stress fibers; (iv) cytoskeletal rearrangements and MLC phosphorylation are inhibited by C3 transferase from Clostridium botulinum, a specific Rho inhibitor, and Y-27632, an inhibitor of Rho kinase; and (v) mox-LDL does not increase intracellular Ca2+concentration. Our data indicate that mox-LDL induces endothelial cell contraction through activation of Rho and its effector Rho kinase which inhibits MLC phosphatase and phosphorylates MLC. We suggest that inhibition of this novel cell signaling pathway of mox-LDL could be relevant for the prevention of atherosclerosis. Mildly oxidized low density lipoprotein (mox-LDL) is critically involved in the early atherogenic responses of the endothelium and increases endothelial permeability through an unknown signal pathway. Here we show that (i) exposure of confluent human endothelial cells (HUVEC) to mox-LDL but not to native LDL induces the formation of actin stress fibers and intercellular gaps within minutes, leading to an increase in endothelial permeability; (ii) mox-LDL induces a transient decrease in myosin light chain (MLC) phosphatase that is paralleled by an increase in MLC phosphorylation; (iii) phosphorylated MLC stimulated by mox-LDL is incorporated into stress fibers; (iv) cytoskeletal rearrangements and MLC phosphorylation are inhibited by C3 transferase from Clostridium botulinum, a specific Rho inhibitor, and Y-27632, an inhibitor of Rho kinase; and (v) mox-LDL does not increase intracellular Ca2+concentration. Our data indicate that mox-LDL induces endothelial cell contraction through activation of Rho and its effector Rho kinase which inhibits MLC phosphatase and phosphorylates MLC. We suggest that inhibition of this novel cell signaling pathway of mox-LDL could be relevant for the prevention of atherosclerosis. mildly oxidized low density lipoprotein horseradish peroxidase human umbilical vein endothelial cell lysophosphatidic acid myosin light chain myosin light chain kinase phosphate-buffered saline The response to injury hypothesis of atherosclerosis proposes that the first step in atherogenesis is an endothelial dysfunction induced by stimuli such as mildly oxidized LDL (mox-LDL)1 (1Ross R. N. Engl. J. Med. 1999; 340: 115-126Crossref PubMed Scopus (18952) Google Scholar). Vascular endothelium exposed to oxidized LDL in vitro and in vivo shows an increased permeability (2Rangaswamy S. Penn M.S. Saidel G.M. Chisolm G.M. Circ. Res. 1997; 80: 73-74Crossref Scopus (73) Google Scholar, 3Liao L. Aw T.Y. Kvietys P.R. Granger D.N. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 2305-2311Crossref PubMed Scopus (44) Google Scholar), a hallmark of endothelial dysfunction. The signal pathways by which mox-LDL and oxidized LDL reduce endothelial barrier function are unknown. Confluent endothelial cells challenged with vasoactive substances, such as thrombin, show a rapid reorganization of their actin cytoskeleton,i.e. stimulation of myosin light chain (MLC) phosphorylation and actin stress fiber formation, leading to cell contraction and intercellular gaps (4Wojciak-Stothard B. Entwistle A. Garg R. Ridley A.J. J. Cell. Physiol. 1998; 176: 150-165Crossref PubMed Scopus (348) Google Scholar, 5Essler M. Amano M. Kruse H-J. Kaibuchi K. Weber P.C. Aepfelbacher M. J. Biol. Chem. 1998; 273: 21867-21874Abstract Full Text Full Text PDF PubMed Scopus (316) Google Scholar). Such cytoskeletal rearrangements reduce endothelial barrier function (6van Hinsbergh V.W.M. Arteriosler. Thromb. Vasc. Biol. 1997; 17: 1018-1023Crossref PubMed Scopus (114) Google Scholar) and are typically found in vivo in endothelium overlying early atherosclerotic lesions (7Colangelo S. Langille B.L. Steiner G. Gotlieb A.I. Arterioscler. Thromb. Vasc. Biol. 1997; 18: 52-56Crossref Scopus (42) Google Scholar). Thrombin induces endothelial cell contraction and increased endothelial permeability through binding to a serpentine receptor which is coupled via heterotrimeric G-proteins of the Gq family to phospholipase Cβ to yield inositol 1,4,5-trisphosphate, which mobilizes Ca2+from intracellular stores and thus increases cytosolic Ca2+concentration (8Grand R.J.A. Turnell A.S. Grabham P.W. Biochem. J. 1996; 313: 353-368Crossref PubMed Scopus (325) Google Scholar). This increase in intracellular Ca2+concentration leads to activation of Ca2+/calmodulin-dependent myosin light chain kinase (MLCK), which phosphorylates Thr-18 and Ser-19 of the MLC of myosin II to enable actin-myosin interaction and cell contraction (9Goeckler Z.M. Wysolmerski R.B. J. Cell Biol. 1995; 130: 613-627Crossref PubMed Scopus (376) Google Scholar). We and others recently found an additional pathway by which thrombin regulates endothelial cell contraction. Thrombin, probably through coupling of the thrombin receptor to heterotrimeric G-proteins of the G12/13 family (10Offermanns S. Laugwitz K.L. Spicher K. Schultz G. Proc. Natl. Acad. Sci. U. S. A. 1993; 91: 504-508Crossref Scopus (388) Google Scholar), was shown to activate the Ras-related GTPase Rho and its effector p160 Rho kinase in endothelial cells (5Essler M. Amano M. Kruse H-J. Kaibuchi K. Weber P.C. Aepfelbacher M. J. Biol. Chem. 1998; 273: 21867-21874Abstract Full Text Full Text PDF PubMed Scopus (316) Google Scholar). Rho kinase phosphorylates myosin binding subunit of MLC phosphatase which is thereby inactivated (11Kimura K. Ito M. Amano M. Chihara K. Fukata Y. Nakafuku M. Yamamori B. Feng Y. Nakano T. Okawa K. Iwamatsu A. Kaibuchi K. Science. 1996; 273: 245-248Crossref PubMed Scopus (2412) Google Scholar, 12Ishizaki T. Maekawa M. Fujisawa K. Okawa K. Iwamatsu A. Fujita A. Watanabe N. Saito Y. Kakizuka A. Morii N. Narumiya S. EMBO J. 1996; 15: 1885-1893Crossref PubMed Scopus (785) Google Scholar, 13Leung T. Chen X. Manser E. Lim L. Mol. Cell. Biol. 1996; 16: 5313-5327Crossref PubMed Google Scholar). Indeed, we observed that thrombin transiently inactivated MLC phosphatase in human endothelial cells and that phosphatase inactivation correlated with peak levels in MLC phosphorylation. Hence, the Rho/Rho kinase pathway seems to regulate endothelial contractility in concert with Ca2+/calmodulin-dependent MLCK. A similar regulatory system was reported in smooth muscle cells (14Gong M.C. Izuka K. Nixon G. Broene J.P. Hall A. Eccleston J.F. Sugai M. Kobayashi S. Somlyo A.V. Somlyo A.P. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 1340-1345Crossref PubMed Scopus (265) Google Scholar, 15Fu X. Gong M.C. Jia T. Somlyo A.V. Somlyo A.P. FEBS Lett. 1998; 440: 183-187Crossref PubMed Scopus (191) Google Scholar, 16Somlyo A.P. Nature. 1997; 389: 908-909Crossref PubMed Scopus (34) Google Scholar). This study was aimed to investigate whether mox-LDL would mimic the action of vasoactive substances on human endothelial cells. We found that (i) mildly oxidized LDL induced a rapid reorganization of the actin cytoskeleton, the formation of intercellular gaps, and the stimulation of MLC phosphorylation within minutes and (ii) that mox-LDL induced these changes through stimulation of the Rho/Rho kinase pathway with the subsequent inhibition of MLC phosphatase and without increasing the cytosolic Ca2+ concentration. Rho kinase inhibitor Y-27632 was kindly provided by Yoshitomi Pharmaceuticals, 3–7-25 Koyata, Iruma-Shi Saitama, Japan. Anti-phospho-MLC antibody was a generous gift from Dr. James Staddon, EISAI Co., London, UK. All other materials not further specified were from Sigma, Deisenhofen, Germany. Human umbilical vein endothelial cells (HUVEC) were obtained and cultured as described previously (5Essler M. Amano M. Kruse H-J. Kaibuchi K. Weber P.C. Aepfelbacher M. J. Biol. Chem. 1998; 273: 21867-21874Abstract Full Text Full Text PDF PubMed Scopus (316) Google Scholar). Before exposure to mox-LDL or native LDL, cells were serum deprived for 15 min. Medium was then replaced by fresh serum-free medium containing mox-LDL or native LDL as indicated. HUVEC were stained for I-actin as described previously (5Essler M. Amano M. Kruse H-J. Kaibuchi K. Weber P.C. Aepfelbacher M. J. Biol. Chem. 1998; 273: 21867-21874Abstract Full Text Full Text PDF PubMed Scopus (316) Google Scholar). For staining of phosphorylated MLC, cells were fixed in 3.7% formaldehyde solution in PBS and permeabilized for 5 min with 0.1% Triton X-100. Cells were treated with normal goat serum (1/10 in PBS) for 20 min and then incubated for 1 h with anti-phospho-MLC antibody, diluted 1/10 in PBS, followed by 1 h incubation with rhodamine-labeled goat anti-rabbit IgG antibody (Dianova, Hamburg, Germany), diluted 1/200 in PBS. MLC phosphorylation was analyzed by SDS-PAGE and Western blotting. HUVEC were grown for 10 days in Costar 6-well culture dishes and treated with mox-LDL as indicated. Cells were lysed with boiling Laemmli buffer. Proteins were then electroblotted onto polyvinylidene difluoride membranes. Membranes were incubated overnight with anti-phospho-MLC antibody (1/500) in Tris-buffered saline containing 0.05% Tween 20, washed three times, incubated for 1 h with horseradish peroxidase-labeled goat anti-rabbit IgG antibody (Amersham Pharmacia Biotech), 1/7500 in Tris-buffered saline, washed three times, and then developed with Luminol solution (Pierce) and exposed to Kodak X-Omat films. The amount of phosphorylated MLC was determined by densitometric analysis of the protein bands that reacted with anti-phospho-MLC antibody, using a Sharp XL-325 densitometer and Amersham Pharmacia Biotech Image Master software. Phosphorylated MLC appeared as a single band of 20 kDa. This 20-kDa band was also detected by a mouse monoclonal antibody to total MLC (Sigma, Deisenhofen, Germany). The lower band is because of an unspecific reaction of the secondary anti-rabbit antibody. The range of linearity of the densitometric measurements of phosphorylated myosin was determined by a dilution series of protein samples of mox-LDL-stimulated HUVEC (4–40 μg of protein/lane). For MLC phosphatase measurement, HUVEC were activated and lysed as described (5Essler M. Amano M. Kruse H-J. Kaibuchi K. Weber P.C. Aepfelbacher M. J. Biol. Chem. 1998; 273: 21867-21874Abstract Full Text Full Text PDF PubMed Scopus (316) Google Scholar). To determine MLC phosphatase activity, we used smooth muscle [α-32P]MLC as a substrate as described previously with some modifications (17Shirazi A. Lizuka K. Fadden P. Mosse C. Somlyo A.P. Somlyo A.V. Haystead T.A. J. Biol. Chem. 1994; 268: 31598-31606Abstract Full Text PDF Google Scholar). Briefly MLC (0.8 mg/ml) was phosphorylated for 1 h at room temperature with MLCK (50 μg/ml) in buffer containing 50 mm Tris-HCl, pH 7.4, 5 mmmagnesium acetate, 0.1 mm CaCl2, 0.1 mg/ml calmodulin, 0.35 m NaCl, 50 μm[α-32P]ATP, passed through 2× 1-ml spin columns with Sephadex G-25 (Amersham Pharmacia Biotech, Uppsala, Sweden), equilibrated with assay buffer, and dialyzed for 18 h at 4 °C with 2 × 5 liters of assay buffer. Phosphatase activities were then quantified by measuring release of radioactivity from [α-32P]MLC in the presence of HUVEC lysates as described (5Essler M. Amano M. Kruse H-J. Kaibuchi K. Weber P.C. Aepfelbacher M. J. Biol. Chem. 1998; 273: 21867-21874Abstract Full Text Full Text PDF PubMed Scopus (316) Google Scholar). LDL was isolated in the continuous presence of EDTA (18Weidtmann A. Scheithe R. Hrboticky N. Pietsch A. Lorenz R. Siess W. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 1131-1138Crossref PubMed Scopus (117) Google Scholar). LDL was dialyzed at 4 °C using a N2-saturated buffer (18Weidtmann A. Scheithe R. Hrboticky N. Pietsch A. Lorenz R. Siess W. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 1131-1138Crossref PubMed Scopus (117) Google Scholar) containing EDTA (1 mm) and then stored at 4 °C in darkness under N2. Mox-LDL was prepared from EDTA-free LDL by Cu2+-triggered oxidation as described (18Weidtmann A. Scheithe R. Hrboticky N. Pietsch A. Lorenz R. Siess W. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 1131-1138Crossref PubMed Scopus (117) Google Scholar). Briefly, freshly dialyzed LDL containing 1 mmol/liter EDTA was loaded onto Econo-PacI0 DG columns (Bio-Rad) and recovered in PBS. LDL was then concentrated to a final concentration of 20 mg/ml by centricon-100 concentrators (Amicon) and mildly oxidized by incubation with CuSO4 (final concentration 640 μmol/liter) for 20 h at 37 °C. The endotoxin concentrations in mox-LDL and native LDL were determined by a Limulus assay and were 5 ng/ml of medium for native LDL and 3.7 ng/ml of medium for mox-LDL. These endotoxin concentrations have no effects on MLC phosphorylation or the actin cytoskeleton of HUVEC within minutes (data not shown). Calcium measurements and calculation of cytosolic Ca2+-concentrations of individual cells were carried out with a Quanticell fluorimetric system (Applied Imaging Corp., Sunderland, UK) as described (19van IJzendoorn S.C. van Gool R.G. Reutelingsperger C.P. Heemskerk J.W. Biochim. Biophys. Acta. 1996; 1311: 64-70Crossref PubMed Scopus (4) Google Scholar). Horseradish peroxidase (HRP) diffusion through HUVEC monolayers was determined as described previously with some modifications (5Essler M. Amano M. Kruse H-J. Kaibuchi K. Weber P.C. Aepfelbacher M. J. Biol. Chem. 1998; 273: 21867-21874Abstract Full Text Full Text PDF PubMed Scopus (316) Google Scholar). HUVEC were cultured for 10 days on collagen-coated cell culture inserts (3-μm pore size, Becton Dickinson) with medium changes every 2 days. For exposure to mox-LDL or native LDL, medium was replaced with 500 μl of culture medium containing mox-LDL or native LDL. For controls mox-LDL was omitted, but otherwise cells were treated identically. After 2 min of stimulation, 500 μl of medium was filled into the lower compartment, and the medium in the upper compartment was replaced with fresh medium containing HRP (0.34 mg/ml, IV-A-type, M r44,000, Sigma, Deisenhofen, Germany). After 1 min, 60 μl of medium was collected from the lower compartment and mixed with 860 μl of reaction buffer (50 mm NaH2PO4, 5 mm Guaiacol) and 100 μl of freshly made H2O2 solution (0.6 mm in H2O). The reaction was allowed to proceed for 15 min at room temperature and absorbance was measured at 470 nm. As shown in Fig. 1, exposure of confluent endothelial monolayers to mox-LDL (250 μg/ml) for 2 min changed their cobblestone morphology with a polygonal cell shape and a dense peripheral actin ring to a contracted phenotype with rounded cells, prominent actin stress fibers, and intercellular gaps (Fig.1 b). To test whether mox-LDL induces actin stress fibers and cell contraction via Rho and Rho kinase, we stained control cells or cells stimulated with mox-LDL for F-actin using rhodamine-phalloidin. As indicated by Fig. 1 a, control cells showed a dense peripheral actin ring and almost no stress fibers. Endothelial cells stimulated with mox-LDL (2 min, 250 μg/ml) showed prominent actin stress fibers and a contracted phenotype with intercellular gaps (Fig.1 b). To investigate whether these actin rearrangements are because of activation of Rho/Rho kinase, we pretreated cells with the selective Rho-inhibitor C3 transferase from Clostridium botulinum (24 h, 5 μg/ml) or the Rho kinase inhibitor Y-27632 (30 min, 10 μm) and then stimulated the cells with mox-LDL. C3 transferase (Fig. 1 c) or Y-27632 (Fig.1 e) did not influence the actin distribution in unstimulated HUVEC, but C3 transferase (Fig. 1 d) and Y-27632 (Fig.1 f) completely blocked the mox-LDL-induced actin stress fiber formation and cell contraction, indicating that mox-LDL induced these cytoskeletal rearrangements through activation of Rho and Rho kinase. In contrast to mox-LDL, native LDL had no effect on the actin cytoskeleton in human endothelial cells (Fig. 1 g). Endothelial cell contraction and intercellular gap formation are expected to increase endothelial permeability. Indeed in our experimental setting, mox-LDL (2 min, 250 μg/ml), but not native LDL, markedly increased transendothelial diffusion of horseradish peroxidase (Fig.2). Pretreatment of cells with C3 transferase (24 h, 5 μg/ml) or Y-27632 (30 min, 10 μm) blocked the mox-LDL-induced increase in permeability. These findings suggest that activation of Rho/Rho kinase is critically involved in mox-LDL-induced increase in endothelial permeability. Phosphorylation of the light chain enables myosin to interact with and to slide against F-actin filaments in stress fibers, which are considered the contractile organelles of non-muscle cells such as endothelial cells (9Goeckler Z.M. Wysolmerski R.B. J. Cell Biol. 1995; 130: 613-627Crossref PubMed Scopus (376) Google Scholar). If in fact mox-LDL stimulates Rho/Rho kinase, this should lead to inhibition of MLC phosphatase followed by MLC phosphorylation (5Essler M. Amano M. Kruse H-J. Kaibuchi K. Weber P.C. Aepfelbacher M. J. Biol. Chem. 1998; 273: 21867-21874Abstract Full Text Full Text PDF PubMed Scopus (316) Google Scholar). Indeed, MLC phosphatase activity was found to be rapidly reduced to about 60% of the basal activity between 30 s and 2 min of mox-LDL treatment, which was followed by a return to base-line values after 5 min (Fig. 3 a). To determine the corresponding levels of phosphorylated MLC, we performed Western blots using a phospho-MLC specific antibody. Fig. 3 b shows a time course of MLC phosphorylation in endothelial cells stimulated with mox-LDL. MLC phosphorylation rose to a peak within 2 min of stimulation and then fell to base-line levels within 15 min. In contrast to mox-LDL, native LDL did not induce MLC phosphorylation in HUVEC. To demonstrate that the mox-LDL-induced MLC phosphorylation is because of Rho/Rho kinase activation, we pretreated HUVEC with C3 transferase (24 h, 5 μg/ml) or Y-27632 (30 min, 10 μm). The results presented in Fig. 4 demonstrate that inhibition of Rho or Rho kinase completely blocked mox-LDL-induced MLC phosphorylation. To investigate the intracellular distribution of phosphorylated MLC in HUVEC after mox-LDL stimulation, cells were stained for phosphorylated MLC. Fig.5 a indicates that in control cells almost no phosphorylated MLC can be detected. In HUVEC treated with mox-LDL (2 min, 250 μg/ml), phosphorylated MLC could be detected that was organized in stress fibers (Fig. 5 b). In cells pretreated with C3 transferase (Fig. 5 c) or with Y-27632 (Fig. 5 d), no incorporation of phosphorylated MLC into stress fibers could be observed. Incubation of cells with native LDL did not induce myosin phosphorylation (Fig. 5 e).Figure 4Mox-LDL-induced MLC phosphorylation is mediated by Rho/Rho kinase. HUVEC were stimulated with mox-LDL (250 μg/ml) as indicated. MLC phosphorylation was then determined by Western blot using an antibody to phosphorylated MLC. The lower molecular weight band is because of an unspecific cross-reaction with the secondary antibody. In cells treated with C3 transferase (24 h, 5 μg/ml) or with Y-27632 (Y) (30 min, 10 μm), mox-LDL-induced (2 min, 250 μg/ml) MLC phosphorylation was completely blocked. A Western blot representative of three similar experiments is shown.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 5. Mox-LDL induces incorporation of phospho-MLC into stress fibers. Human endothelial cells were not stimulated (a), stimulated with mox-LDL (2 min, 250 μg/ml) (b), treated with C3 transferase (24 h, 5 μg/ml) and then stimulated with mox-LDL (c), pretreated with Y-27632 (30 min, 10 μm) and then stimulated with mox-LDL (d), or treated with n-LDL (2 min, 250 μg/ml) (e). Cells were then fixed and stained for phosphorylated MLC.View Large Image Figure ViewerDownload Hi-res image Download (PPT) To study whether an increase in cytosolic Ca2+ concentration and subsequent MLCK activation also contributes to the mox-LDL-induced MLC phosphorylation, we measured cytosolic Ca2+ concentrations. Fig.6 indicates that mox-LDL does not increase cytosolic Ca2+ concentration in HUVEC indicating that it enhances MLC phosphorylation in HUVEC mainly through the Rho/Rho kinase pathway. Here we describe a novel signal pathway of mox-LDL in human endothelial cells. Mox-LDL induces cell contraction, i.e.formation of actin stress fibers and intercellular gaps, leading to an increase in endothelial permeability, through activation of the Rho/Rho kinase pathway. This mechanism potentially contributes to endothelial dysfunction in early atherosclerotic lesions. Down-regulation of MLC phosphatase could also be a mechanism by which mox-LDL enhances the effects of Ca2+-mobilizing vasoactive substances. Conceivably, continuous stimulation of the vascular endothelium by subendothelial mox-LDL may eventually lead to an enhanced susceptibility of the endothelium to such vasoactive substances. Our data indicate that mox-LDL utilizes physiologic signal mechanisms to activate the endothelium. Although we have not determined in the present study the mox-LDL-stimulated signal pathways upstream of Rho, we suggest that mox-LDL stimulates the Rho/Rho kinase pathway in endothelial cells through activation of heterotrimeric G-protein-coupled receptors such as the lysophosphatidic acid (LPA) receptor. We have indeed recently found that LPA is formed during mild oxidation of LDL in the absence of cells and that LPA was the main ingredient in mox-LDL responsible for the induction of platelet shape change and endothelial cell activation (21Siess W. Zangl K.J. Essler M. Bauer M. Brandl R. Corrinth C. Bittman R. Tigyi G. Aepfelbacher M. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 6931-6936Crossref PubMed Scopus (366) Google Scholar). In fibroblasts, LPA induces Rho-dependent stress fiber formation through activation of G13 (22Gohla A. Harhammer R. Schultz G. J. Biol. Chem. 1998; 273: 4653-4659Abstract Full Text Full Text PDF PubMed Scopus (234) Google Scholar) and enhances contractility by this way (23Chrzanowska-Wodnicka M. Burridge K. J. Cell Biol. 1996; 133: 1403-1415Crossref PubMed Scopus (1384) Google Scholar). Activation of Rho and Rho kinase by mox-LDL may not be restricted to endothelial cells. It is likely that mox-LDL activates the same pathway in smooth muscle cells and fibroblasts. Indeed, it is well documented that Rho kinase plays a pivotal role for Ca2+ sensitization of vascular smooth muscle cells. Furthermore mox-LDL was found to induce vascular smooth muscle cell contraction (24Augé N. Fitoussi G. Bascands J-L. Pieraggi M-T. Junquero D. Valet P. Girolami J-P. Salvayre R. Negre-Salvayre A. Circ. Res. 1996; 79: 871-880Crossref PubMed Scopus (25) Google Scholar). Hence mox-LDL could contribute to elevated levels of blood pressure by activation of Rho kinase and thereby enhanced contractility of smooth muscle cells. Indeed, the Rho kinase inhibitor Y-27632 has previously been found to reduce the blood pressure in hypertensive rats (25Uehata M. Ishizaki T. Satoh H. Ono T. Kawahara T. Morishita T. Tamakawa H. Yamagami K. Inui J. Maekawa M. Narumiya S. Nature. 1997; 389: 990-994Crossref PubMed Scopus (2507) Google Scholar). In conclusion, we propose that the Rho/Rho kinase pathway is critical for the activation of endothelial cells by mox-LDL and could be a new target to prevent atherogenesis and cardiovascular disease. We thank Carola Meister and Barbara Böhlig for expert technical assistance and Prof. P. C. Weber, Institut für Prophylaxe der Kreislaufkrankheiten for support. Smooth muscle MLC and MLCK were a generous gift from Kozo Kaibuchi, Nara Institute of Science and Technology, Ikoma, Japan. Anti-phospho-MLC antibody was kindly provided by Dr. J. M. Staddon, Eisai Co., London, UK.